nach oben

International Journal of Diabetes in Developing Countries

Erschienen in:

01.11.2015 | Original Article

Comparison of salivary nitric oxide and epidermal growth factor level between diabetic patients and healthy individuals

verfasst von: Hamid Reza Abdolsamadi, Fatemeh Rezaei, Mohammad Taghi Goodarzi, Abbas Moghimbeigi, Mina Jazaeri, Soheila Asadi, Fatemeh Ahmadi-Motamayel

Erschienen in: International Journal of Diabetes in Developing Countries | Sonderheft 3/2015

Einloggen, um Zugang zu erhalten

Abstract

The purpose of the current study was to compare salivary Nitric oxide and epidermal growth factor level in diabetic patients and healthy individuals. In this paired-control study 20 patients with type 1 diabetes mellitus, 20 patients with type 2 diabetes mellitus and 20 age and sex matched healthy subjects participated. The level of salivary Nitric oxide was increased in type 1 and 2 diabetic patients in comparison to control individuals (P = 0.037 and P = 0.058), respectively. Epidermal growth factor concentration was higher in type 1 and 2 diabetic patients compare to healthy ones, (P = 0.037 and P = 0.005) respectively. There was no significant difference between salivary Nitric oxide and Epidermal growth factor level regarding to the type of diabetes (P > 0.05). Significant statistical correlation was found between Nitric oxide and Epidermal growth factor levels and the fasting blood glucose and HbA1c (P < 0.001). Conclusions: Salivary Nitric oxide and Epidermal growth factor levels were higher in type 1 and type 2 diabetic patients and there was correlation with severity of disease.

Power A. Diabetes mellitus. In: Fauci AS, Kasper DL, Longo DL, Braunwald E, Hauser SL, Jameson L, et al., editors. Harrison’s principls of internal medicine. 18th ed. New York: McGraw-Hill; 2012. p. 2152–80.

Castagnola M, Picciotti PM, Messana I, et al. Potential applications of human saliva as diagnostic fluid. Acta Otorhinolaryngol Ital. 2011;31:347–57.PubMedPubMedCentral

Liu JDY. Saliva: a potential media for disease diagnostics and monitoring. Oral Oncol. 2012;18.

Marletta MA. Nitric oxide synthase structure and mechanism. J Biol Chem. 1993;269:12231–4.

Sunitha M, Shanmugam S. Evaluation of salivary nitric oxide levels in oral mucosal diseases: a controlled clinical trial. Indian J Dent Res. 2006;17:117–20.PubMedCrossRef

Nagy G, Koncz A, Telarico T, et al. Central role of nitric oxide in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther. 2010;12:210.PubMedPubMedCentralCrossRef

Wilsher ML, Fergusson W, Milne D, et al. Exhaled nitric oxide in sarcoidosis. Thorax. 2005;60:967–70.PubMedPubMedCentralCrossRef

Schildge J. Nitric oxide in exhaled breath of patients with interstitial lung diseases. Pneumologie. 2011;65:143–8.PubMedCrossRef

Yalcin AD, Gorczynski RM, Parlak GE, et al. Total antioxidant capacity, hydrogen peroxide, malondialdehyde and total nitric oxide concentrations in patients with severe persistent allergic asthma: its relation to omalizumab treatment. Clin Lab. 2012;58:89–96.PubMed

10.

Farhad AR, Razavi S, Jahadi S, et al. Use of aminoguanidine, a selective inducible nitric oxide synthase inhibitor, to evaluate the role of nitric oxide in periapical inflammation. J Oral Sci. 2011;53:225–30.PubMedCrossRef

11.

Kim KA, Shin YJ, Kim JH, et al. Dysfunction of endothelial progenitor cells under DM conditions and its underlying mechanisms. Arch Pharm Res. 2012;35:223–34.PubMedCrossRef

12.

Shoukry A, Shalaby SM, Abdelazim S, et al. Endothelial nitric oxide synthase gene polymorphisms and the risk of diabetic nephropathy in type 2 diabetes mellitus. Genet Test Mol Biomarkers. 2012;16(6):574–9.PubMedCrossRef

13.

Abu-Saleh N, Ovcharenko E, Awad H, et al. Involvement of the endothelin and nitric oxide systems in the pathogenesis of renal ischemic damage in an experimental DM model. Life Sci. 2012;17.

14.

Maritim AC, Sanders RA, Watkins 3rd JB. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol. 2003;17:24–38.PubMedCrossRef

15.

Carpenter G, Cohen S. Epidermal growth factor. Annu Rev Biochem. 1979;48:193–216.PubMedCrossRef

16.

Niall M, Ryan G, O’Brien BM. The effect of epidermal growth factor on wound healing in mice. J Surg Res. 1982;33:164–9.PubMedCrossRef

17.

Noguchi S, Ohba Y, Oka T. Effect of salivary epidermal growth factor on wound healing of tongue in mice. Am J Physiol. 1991;260:E620–5.PubMed

18.

Lee HY, Yea K, Kim J, et al. Epidermal growth factor increases insulin secretion and lowers blood glucose in DM mice. J Cell Mol Med. 2008;12:1593–604.

19.

Yu H, Sun Z, Cui J, et al. Epidermal growth factor and gastrin on PDX1 expression in experimental type 1 DM rats. Am J Med Sci. 2012;343:141–5.

20.

Loukovaara M, Leinonen P, Teramo K, et al. DM pregnancy associated with increased epidermal growth factor in cord serum at term. Obstet Gynecol. 2004;103:240–4.

21.

Lao G, Yan L, Yang C, et al. Controlled release of epidermal growth factor from hydrogels accelerates wound healing in DM rats. J Am Podiatr Med Assoc. 2012;102:89–98.

22.

Nagy A, Nagashima H, Cha S, et al. Reduced oral wound healing in the NOD mouse model for type 1 autoimmune diabetes and its reversal by epidermal growth factor supplementation. Diabetes. 2001;50:2100–4.PubMedCrossRef

23.

WHO. The use and interpretation of anthropometry. Geneva: WHO; 1995.

24.

Navazesh M, Kumar SK. Measuring salivary flow: challenges and opportunities. J Am Dent Assoc. 2008;139:35S–40S.PubMedCrossRef

25.

Astaneie F, Afshari M, Mojtahedi A, et al. Total antioxidant capacity and levels of epidermal growth factor and nitric oxide in blood and saliva of insulin-dependent DM patients. Arch Med Res. 2005;36:376–81.PubMedCrossRef

26.

Oxford GE, Tayari L, Barfoot MD, et al. Salivary EGF levels reduced in DM patients. J Diabetes Complications. 2000;14:140–5.PubMedCrossRef

27.

Ohashi M, Iwase M, Nagumo M. Elevated production of salivary nitric oxide in oral mucosal diseases. J Oral Pathol Med. 1999;28:355–9.PubMedCrossRef

28.

Ahdi M, Gerdes V, Hoekstra JB, et al. Diabetes mellitus. Ned Tijdschr Tandheelkd. 2012;119:65–71.PubMedCrossRef

29.

Mocada S, Palmer R, Higgs EA. Nitric oxide, physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43:109–42.

30.

Sessa WC, Prichard K, Seyedi N, et al. Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. Circ Res. 1994;74:349–53.PubMedCrossRef

31.

Abdollahi M, Zadehkabir R, Rahmat-jirdeh N, et al. Interaction of L-arginine/nitric oxide system with lead acetate on secretion of amylase from isolated rat parotid glands. DARU. 2001;1:50–7.

32.

Abou-Seif MA, Youssef A. Evaluation of some biochemical changes in DM patients. Clin Chim Acta. 2004;346:161–70.PubMedCrossRef

33.

Takeda M, Mori F, Yoshida A, Takamiya A, et al. Constitutive nitric oxide synthase is associated with retinal vascular permeability in early DM rats. Diabetologia. 2001;44:1043–50.PubMedCrossRef

34.

DeVries AS, Stoenoiu MS, Elger M, et al. Diabetes-induced microvascular dysfunction in the hydronephrotic kidney; role of nitric oxide. Kidney Int. 2001;60:202–10.CrossRef

35.

Volk T, Loannidis I, Hensel M, et al. Endothelial damage induced by nitric oxide synergism with reactive oxygen species. Biophys Res Commun. 1995;213:1196–203.CrossRef

36.

Reher VG, Zenobio EG, Costa FO, et al. Nitric oxide levels in saliva increase with severity of chronic periodontitis. J Oral Sci. 2007;49:271–6.PubMedCrossRef

37.

Das D, Bandyopadhyay D, Bhattacharjee M, et al. Hydroxyl radical is the major causative factor in stress induced gastric ulceration. Free Radic Biol Med. 1997;23:8–18.PubMedCrossRef

38.

Kasayama S, Ohba Y, Oka T. Epidermal growth factor deficiency associated with diabetes mellitus. Proc Natl Acad Sci U S A. 1989;86:7644–8.PubMedPubMedCentralCrossRef

39.

Hu Y, Nakagawa Y, Purushotham KR, et al. Functional changes in salivary glands of autoimmune disease-prone NOD mice. Am J Physiol. 1992;263:E607–14.PubMed

40.

Kim SK, Cuzzort LM, Mskean RK, et al. Effects of diabetes and insulin on a-amylase messenger RNA levels in rat parotid glands. J Dent Res. 1990;69:1500–4.PubMedCrossRef

41.

Yu H, Sun Z, Cui J, et al. Epidermal growth factor and gastrin on PDX1 expression in experimental type 1. Am J Med Sci. 2012;343:141–5.PubMedCrossRef

42.

Suarez-Pinzon WL, Yan Y, Power R, et al. Combination therapy with epidermal growth factor and gastrin increases beta-cell mass and reverses hyperglycemia in DM NOD mice. Diabetes. 2005;54:2596–601.PubMedCrossRef

43.

Knighton D R, Fiegel VD. Growth factor and comprehensive surgical care of DM wounds. Curr Opin Gen Surg. 1993;32–9.

44.

Olsen PS, Poulsen SS, Kirkagaard P, et al. Role of submandibular gland saliva and epidermal growth factor in gastrin cytoprotection. Gastroenterology. 1984;87:103–8.PubMed

45.

Tsang MW, Wong WK, Hung CS, et al. Human epidermal growth factor enhances healing of DM foot ulcers. Diabetes Care. 2003;26:1856–61.PubMedCrossRef

46.

Zelles T, Purushotham K, Macauley SP, et al. Saliva and growth factors: the fountain of youth resides in us all. J Dent Res. 1995;74:1826–32.PubMedCrossRef

47.

Sreebny LM, Yu A, Green A, et al. Xerostomia in diabetes mellitus. Diabetes Care. 1992;15:900–4.PubMedCrossRef

48.

Marotta PS, Fontes T, Armada L, et al. Type 2 diabetes mellitus and the prevalence of apical periodontitis and. J Endod. 2012;38:297–300.PubMedCrossRef

49.

Hormia M, Thesleff I, Perheentupa J, et al. Increased rate of salivary epidermal growth factor secretion in patients with juvenile periodontitis. Scand J Dent Res. 1993;101:138–44.PubMed

Titel: Comparison of salivary nitric oxide and epidermal growth factor level between diabetic patients and healthy individuals
verfasst von: Hamid Reza Abdolsamadi
Fatemeh Rezaei
Mohammad Taghi Goodarzi
Abbas Moghimbeigi
Mina Jazaeri
Soheila Asadi
Fatemeh Ahmadi-Motamayel
Publikationsdatum: 01.11.2015
Verlag: Springer India
Erschienen in: International Journal of Diabetes in Developing Countries / Ausgabe Sonderheft 3/2015
Print ISSN: 0973-3930
Elektronische ISSN: 1998-3832
DOI: https://doi.org/10.1007/s13410-014-0207-x

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Comparison of salivary nitric oxide and epidermal growth factor level between diabetic patients and healthy individuals

Abstract

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 3/2015

Glomerular filtration rate-based cystatin C compared to microalbuminuria to detect early stage of diabetic nephropathy in children with type 1 diabetes mellitus

Heparanase activity as a prospective marker for diabetic nephropathy in Egyptian patients with type 2 diabetes mellitus

The eye and the kidney: twin targets in diabetes

Association of serum ferritin concentrations with prevalence of prediabetes, type 2 diabetes mellitus, and metabolic syndrome in a Chinese population from Sichuan

Decreased blood levels of glyoxalase I and diabetic complications

Double-blind randomized placebo-controlled trial to compare the effects of gabapentin, pregabalin and tramadol + acetaminophen combination in improvement of pain in patients with painful diabetic neuropathy